Charming Medical (MCTA)
Market Price (12/4/2025): $29.0 | Market Cap: $-Sector: Health Care | Industry: Health Care Facilities
Charming Medical (MCTA)
Market Price (12/4/2025): $29.0Market Cap: $-Sector: Health CareIndustry: Health Care Facilities
Investment Highlights
Why It Matters
Which of these 2 stories sounds closer for this stock?
1. Generates cash flow
The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.
2. Riding a trend
Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow
| Megatrend and thematic driversMegatrends include Precision Medicine, and Digital Health & Telemedicine. Themes include Personalized Diagnostics, Targeted Therapies, Show more. |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Digital Health & Telemedicine. Themes include Personalized Diagnostics, Targeted Therapies, Show more. |
Valuation, Metrics & Events
MCTA Stock
Why The Stock Moved
Qualitative Assessment
AI Generated Analysis | Feedback
Here are the key points for Charming Medical (MCTA) stock movement from August 31, 2025, to December 4, 2025:
1. Initial Public Offering (IPO) and Nasdaq Listing: Charming Medical priced its Initial Public Offering at $4.00 per share on October 21, 2025, and its shares began trading on the Nasdaq Capital Market under the ticker symbol "MCTA." This event marked its entry into the public market, which typically generates significant investor interest and initial price fluctuations. The company aimed to raise approximately $6.4 million in gross proceeds from the IPO.
2. Strong Investor Demand Post-IPO: Following its IPO, Charming Medical experienced robust investor optimism, evidenced by the full exercise of the underwriter's over-allotment option by October 28, 2025. This increased the total gross proceeds from the offering to approximately $7.36 million, indicating strong demand for its shares.
Stock Movement Drivers
Return vs. Risk
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| MCTA Return | - | - | - | - | - | - | |
| Peers Return | 13% | 5% | 9% | -1% | -12% | -15% | -4% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 16% | 112% |
Monthly Win Rates [3] | |||||||
| MCTA Win Rate | - | - | - | - | - | - | |
| Peers Win Rate | 15% | 15% | 15% | 10% | 6% | 25% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 70% | |
Max Drawdowns [4] | |||||||
| MCTA Max Drawdown | - | - | - | - | - | - | |
| Peers Max Drawdown | -16% | -0% | -4% | -5% | -13% | -16% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: ACHC, AMTU, AVG, MCTA, SRTA.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/3/2025 (YTD)
How Low Can It Go
MCTA has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -16.1% | -25.4% |
| % Gain to Breakeven | 19.1% | 34.1% |
| Time to Breakeven | 599 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -28.8% | -33.9% |
| % Gain to Breakeven | 40.4% | 51.3% |
| Time to Breakeven | 116 days | 148 days |
| 2018 Correction | ||
| % Loss | -15.8% | -19.8% |
| % Gain to Breakeven | 18.8% | 24.7% |
| Time to Breakeven | 326 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -40.6% | -56.8% |
| % Gain to Breakeven | 68.3% | 131.3% |
| Time to Breakeven | 1100 days | 1480 days |
Compare to
In The Past
SPDR Select Sector Fund's stock fell -16.1% during the 2022 Inflation Shock from a high on 4/8/2022. A -16.1% loss requires a 19.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
Trade Ideas
Select past ideas related to MCTA. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 4.1% | 4.1% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -9.8% | -9.8% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 6.0% | 6.0% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 9.7% | 9.7% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 6.2% | 6.2% | -5.1% |
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 4.1% | 4.1% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -9.8% | -9.8% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 6.0% | 6.0% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 9.7% | 9.7% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 6.2% | 6.2% | -5.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Charming Medical
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 9.56 |
| Mkt Cap | 1.3 |
| Rev LTM | 1,760 |
| Op Inc LTM | 210 |
| FCF LTM | -183 |
| FCF 3Y Avg | -142 |
| CFO LTM | 168 |
| CFO 3Y Avg | 145 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 5.6% |
| Rev Chg 3Y Avg | 22.7% |
| Rev Chg Q | 4.3% |
| QoQ Delta Rev Chg LTM | 1.1% |
| Op Mgn LTM | 2.0% |
| Op Mgn 3Y Avg | -2.9% |
| QoQ Delta Op Mgn LTM | 1.0% |
| CFO/Rev LTM | 5.4% |
| CFO/Rev 3Y Avg | 0.6% |
| FCF/Rev LTM | -9.2% |
| FCF/Rev 3Y Avg | -11.2% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 1.3 |
| P/S | 0.7 |
| P/EBIT | 8.2 |
| P/E | 20.9 |
| P/CFO | 6.7 |
| Total Yield | 4.8% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -7.6% |
| D/E | 1.1 |
| Net D/E | 1.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -22.0% |
| 3M Rtn | -15.0% |
| 6M Rtn | -35.0% |
| 12M Rtn | -65.2% |
| 3Y Rtn | -83.2% |
| 1M Excs Rtn | -22.0% |
| 3M Excs Rtn | -21.2% |
| 6M Excs Rtn | -49.7% |
| 12M Excs Rtn | -77.4% |
| 3Y Excs Rtn | -155.4% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 3312025 | 7302025 | F-1/A 3/31/2025 |
| 3312024 | 5142025 | F-1 3/31/2024 |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |